Target Name: FFAR2
NCBI ID: G2867
Review Report on FFAR2 Target / Biomarker Content of Review Report on FFAR2 Target / Biomarker
FFAR2
Other Name(s): G-protein coupled receptor 43 | free fatty acid activated receptor 2 | free fatty acid receptor 2 | FFA2R | G protein-coupled receptor 43 | fatty acid receptor 2 | Free fatty acid receptor 2, transcript variant 1 | Tree fatty acid activated receptor 2 | FFAR2_HUMAN | FFAR2 variant 1 | Free fatty acid receptor 2 | GPR43

Study on GPCR43: Potential Drug Target and Biomarker

G-protein coupled receptor 43 (GPCR43) is a protein that plays an important role in cellular signaling. It is a member of the GPCR family, which includes over 700 different proteins that regulate a wide range of cellular processes. GPCR43 is one of the most well-studied GPCR proteins, and a number of potential drug targets and biomarkers have been identified.

GPCR43 is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, and heart. It is a G-protein-coupled receptor, which means that it is characterized by the presence of a nucleotide-binding oligomerization domain (NBD) and a transmembrane region. The NBD is a protein that can interact with small molecules, such as drugs, and is thought to play a role in modulating the activity of GPCR43. The transmembrane region is responsible for the protein's ability to interact with G proteins, which are signaling molecules that can activate or inhibit a wide range of cellular processes.

GPCR43 is involved in a wide range of cellular signaling pathways. For example, it is thought to be involved in the regulation of neurotransmitter release from neurons, as well as the modulation of pain perception. It is also involved in the regulation of inflammation, and has been shown to play a role in the development of certain diseases, such as cancer.

Due to its involvement in a wide range of cellular signaling pathways, GPCR43 is a potential drug target. Many drugs that are currently in use are designed to modulate the activity of GPCR43, with a focus on modulating its activity in the brain. For example, one class of drugs that are commonly used to treat anxiety and depression is a subclass of GPCR43 antagonists, which are believed to work by modulating the activity of GPCR43 in the brain.

Another class of drugs that are being developed to treat GPCR43-related diseases is a subclass of GPCR43 modulators, which are designed to modulate the activity of GPCR43 in a specific way. For example, some drugs that are being developed to treat addiction are thought to work by modulating the activity of GPCR43 in the brain, potentially by modulating the release of dopamine.

In addition to its potential as a drug target, GPCR43 is also a potential biomarker. The ability of GPCR43 to interact with small molecules makes it a useful target for the development of small molecule probes, which can be used to study the activity of GPCR43 in a specific way. For example, one type of small molecule probe that is being used to study the activity of GPCR43 is called a GPCR43 agonist, which is a compound that can activate the activity of GPCR43.

Research into GPCR43 is still an active area of study, and many questions about its function and potential as a drug target or biomarker remain to be answered. However, the studies that have been done to date suggest that GPCR43 is a complex protein that plays an important role in cellular signaling, and that it is an attractive target for the development of new drugs.

Protein Name: Free Fatty Acid Receptor 2

Functions: G protein-coupled receptor that is activated by a major product of dietary fiber digestion, the short chain fatty acids (SCFAs), and that plays a role in the regulation of whole-body energy homeostasis and in intestinal immunity. In omnivorous mammals, the short chain fatty acids acetate, propionate and butyrate are produced primarily by the gut microbiome that metabolizes dietary fibers. SCFAs serve as a source of energy but also act as signaling molecules. That G protein-coupled receptor is probably coupled to the pertussis toxin-sensitive, G(i/o)-alpha family of G proteins but also to the Gq family (PubMed:12496283, PubMed:12711604, PubMed:23589301). Its activation results in the formation of inositol 1,4,5-trisphosphate, the mobilization of intracellular calcium, the phosphorylation of the MAPK3/ERK1 and MAPK1/ERK2 kinases and the inhibition of intracellular cAMP accumulation. May play a role in glucose homeostasis by regulating the secretion of GLP-1, in response to short-chain fatty acids accumulating in the intestine. May also regulate the production of LEP/Leptin, a hormone acting on the central nervous system to inhibit food intake. Finally, may also regulate whole-body energy homeostasis through adipogenesis regulating both differentiation and lipid storage of adipocytes. In parallel to its role in energy homeostasis, may also mediate the activation of the inflammatory and immune responses by SCFA in the intestine, regulating the rapid production of chemokines and cytokines. May also play a role in the resolution of the inflammatory response and control chemotaxis in neutrophils. In addition to SCFAs, may also be activated by the extracellular lectin FCN1 in a process leading to activation of monocytes and inducing the secretion of interleukin-8/IL-8 in response to the presence of microbes (PubMed:21037097). Among SCFAs, the fatty acids containing less than 6 carbons, the most potent activators are probably acetate, propionate and butyrate (PubMed:12496283, PubMed:12711604). Exhibits a SCFA-independent constitutive G protein-coupled receptor activity (PubMed:23066016)

The "FFAR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FFAR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14